Cross-Sector entity

DEA (Drug Enforcement Administration)

Company
6

All 1 tracked stories fall under one category: regulation. DEA (Drug Enforcement Administration) is most often covered alongside Dr. Luli Akinfiresoye, which appears in 1 of these 1 story. We currently track 1 Cross-Sector story that mention DEA (Drug Enforcement Administration), all published on July 27, 2026.

1 verified story tracked

Last mentioned: Jul 27, 2026

RSS updates
Share

Entity pulse

Recent coverage · DEA (Drug Enforcement Administration)

1 story
6 avg impact
0% positive
100% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.

  • 100% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about DEA (Drug Enforcement Administration)

All 1 tracked stories fall under one category: regulation. DEA (Drug Enforcement Administration) is most often covered alongside Dr. Luli Akinfiresoye, which appears in 1 of these 1 story. We currently track 1 Cross-Sector story that mention DEA (Drug Enforcement Administration), all published on July 27, 2026. Each carries 2 original sources on average.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering DEA (Drug Enforcement Administration). Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Rescheduling Hearing Testimony

    Under subpoena, Dr. Akinfiresoye testifies in the marijuana rescheduling proceeding that marijuana fails the first three factors of the DEA's five-factor test, directly contradicting the HHS Schedule III recommendation.

  2. DEA Scientific Data Review Published

    Dr. Luli Akinfiresoye authors the DEA's internal Scientific Data Review on marijuana, reportedly concluding that marijuana lacks sufficient, reproducible scientific evidence for accepted medical use.

Stories mentioning DEA (Drug Enforcement Administration) 1

Legal regulation Negative 6

DEA's Own Expert: Marijuana Fails 3 of 5 Medical Use Factors—Order at Risk

DEA pharmacologist Dr. Luli Akinfiresoye testified that marijuana fails the agency's historical scientific standard for accepted medical use, directly contradicting the HHS recommendation to reschedule. This intra-agency conflict exposes the proposed Schedule III rule to a likely arbitrary-and-capricious challenge, redefining the evidentiary landscape for controlled substance rulemaking.

2 sources

Source: newjerseytelegraph.com · pr-inside.com